Loading...
PhD Helena Podgornik

PhD Helena Podgornik
no.: 12684 source: ARIS

researcher – active in research organisation
E-mail helena.podgornikat signkclj.si
Foreign language skills
Research activity

Code Science Field Subfield
3.01.00  Medical sciences  Microbiology and immunology   
4.06.04  Biotechnical sciences  Biotechnology  Microbe biotechnology 

Code Science Field
B220  Biomedical sciences  Genetics, cytogenetics 
B200  Biomedical sciences  Cytology, oncology, cancerology 
B190  Biomedical sciences  Clinical chemistry 
Keywords
cytogenetics, leukemia, citology, haematology, personalised medicine
Points
382.63
A''
73.21
A'
176.68
A1/2
216.27
CI10
500
CImax
158
h10
10
A1
1.33
A3
0.57
Data for the last 5 years (citations for the last 10 years) on July 14, 2024; A3 for period 2018-2022 (update for tender in 2023: YES)
Data for ARIS tenders ( 21.05.2024 – Target research programmes, archive )
Database Linked records Citations Pure citations Average pure citations
WoS 68  739  656  9.65 
Scopus 61  840  716  11.74 
Mentoring junior researchers
source: ARIS
no. Name and surname Type Period Code
1 PhD Katarina Reberšek  Bologna doctoral studies  11/1/2007 - 5/12/2014  29594 
Education
source: ARIS
Level of education Professional title Study subject Faculty Year
    Chem.engineering  SI 1991 
Master's degree    Biochemistry  SI University of Ljubljana, Faculty of Chemistry and Chemical Technology 1995 
Doctor's degree  Ph. D.   Biochemistry  SI Univeristy of Ljubljana, Faculty of Chemistry and Chemical Technology 2000 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group Date of employment Position Role Title
Full time employment (100%, RD:20%)  University Medical Centre Ljubljana  Department of Haematology  1/13/2003    Researcher   
Research projects Legend
source: ARIS
no. Code Title Period Head No. of publications
1. J3-50116  Matters of the heart: elucidating the cardiotoxic mechanism of proteasome inhibitors   2023 - 2024  PhD Martina Gobec  2,239 
2. J7-4640  Innovative CAR T cell cancer immunotherapy (CARRS)   2022 - 2024  PhD Roman Jerala  4,209 
3. J7-2603  EFFICACY OF BACTERIOPHAGES FOR TREATEMENT OF EXTRACELULAR AND INTRACELULAR BACTERIAL INFECTIONS OF IMPLANTANTS   2020 - 2023  PhD Aleš Podgornik  2,333 
4. J3-1752  APOPTOSIS TARGETING OF LEUKEMIC CELLS IN CHRONIC MYELOID LEUKEMIA USING Cas9 – TargetCML9   2019 - 2022  PhD Matjaž Sever  2,642 
5. L3-9279  Genetic basis of erythrocytosis in Slovenia   2019 - 2020  PhD Nataša Debeljak  3,135 
6. J3-4313  The influence of active transport and patients' genotypes on the therapeutic outcome of chronic myeloic leukemia   2011 - 2014  PhD Albin Kristl  3,148 
7. J3-0161  VPLIV METABOLITOV ARZENOVEGA TRIOKSIDA NA ZDRAVLJENJE AKUTNE PROMIELOCITNE LEVKEMIJE IN MULTIPLEGA MIELOMA (Slovene)   2008 - 2011  PhD Zdenka Šlejkovec  3,052 
8. L3-6011  Osamitev, karakterizacija in diferenciacija humane matične celice kot podlaga celični terapiji (Slovene)   2004 - 2007  PhD Primož Rožman  2,317 
9. J3-6104  Biotransformacija As203 in njen vpliv na učinkovitost zdravljenja APL (Slovene)   2004 - 2007  PhD Zdenka Šlejkovec  2,990 
10. L2-3529  Konvekcija pri pripravi velikih monolitov, njihova hidrodinamika in miniaturizacija (Slovene)   2002 - 2004  PhD Aleš Podgornik  2,150 
11. Z2-3538  Methodology for optimization of biological wastewater treatment plant operation using toxicity and biodegradability testing of the wastewaters   2002 - 2004  PhD Andreja Žgajnar Gotvajn  1,804 
12. L4-3068  Uporaba ligninolitičnih encimov gliv bele trohnobe za razgradnjo sintetičnih barvil (Slovene)   2002 - 2004  PhD Helena Podgornik  3,561 
13. L4-1555  Razgradja barvil z ekstracelularnimi encimi glive phanerochaete chrysosporium (Slovene)   2000 - 2001  PhD Marin Berovič  2,089 
14. J4-8846  Fungal metabolites   1999  PhD Aleksa Cimerman  1,225 
15. J4-7453  Primerjalne raziskave askomicetnih in bazidiomicetnih gliv (Slovene)   1996 - 1998  PhD Katarina Jernejc  1,922 
ARIS research and infrastructure programmes Legend
source: ARIS
Views history
Favourite